Assure Laboratory INC

Assure Laboratory INC was paid $403K by Medicaid between Nov 2020 and Sep 2023, across 90 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 76% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in South Carolina

Rank by total paid#20 of 39

Median peer was paid$403K

This provider vs. median1.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	245	$17K
2021	1,879	$121K
2022	27,522	$129K
2023	17,692	$136K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	76%	3,788	1,099	$306K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	8.5%	1,648	489	$34K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	3.3%	373	121	$13K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.1%	2,228	1,340	$4K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	499	343	$3K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	222	127	$3K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	793	245	$3K
84443	Thyroid stimulating hormone (TSH)	<1%	2,500	1,474	$2K
87150		<1%	410	114	$2K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	257	190	$2K
87631		<1%	115	66	$2K
80061	Lipid panel	<1%	2,892	1,749	$2K

78 more codes

80053	Comprehensive metabolic panel	<1%	3,521	$2K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	3,558	$2K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	1,971	$2K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	114	$1K
82607		<1%	1,439	$1K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,722	$1K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	75	$1K
84481		<1%	651	$984.73
82728		<1%	980	$697.31
82746		<1%	783	$678.65
87581		<1%	253	$603.85
87486		<1%	253	$602.09
84439		<1%	1,149	$578.40
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	210	$506.70
86803		<1%	519	$501.89
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	351	$481.12
84681		<1%	368	$455.22
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	210	$454.37
84403		<1%	328	$430.75
86376		<1%	378	$364.23
83540		<1%	981	$360.56
86800		<1%	310	$360.39
87517		<1%	53	$334.17
83550		<1%	701	$319.55
84153		<1%	295	$319.14
36415	Collection of venous blood by venipuncture	<1%	2,724	$316.35
86141		<1%	285	$305.55
86704		<1%	379	$303.76
83735		<1%	677	$293.48
87086	Culture, bacterial; quantitative colony count, urine	<1%	627	$272.38
86709		<1%	423	$269.56
83525		<1%	372	$250.11
82670		<1%	76	$207.34
87340		<1%	318	$195.45
87500		<1%	160	$191.58
87641		<1%	152	$175.12
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	139	$166.71
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	88	$131.47
85060		<1%	106	$129.47
84436		<1%	427	$127.95
82043		<1%	412	$124.49
84270		<1%	95	$122.69
80050	General health panel	<1%	210	$122.21
87522	Neg quan hep c or qual rna	<1%	35	$107.10
83002		<1%	64	$106.56
86706		<1%	79	$104.27
86592		<1%	296	$101.40
87481		<1%	245	$96.09
84154		<1%	79	$75.05
87653		<1%	179	$74.37
86705		<1%	68	$71.84
86431		<1%	201	$68.71
83001		<1%	43	$65.08
87640		<1%	165	$60.33
86696		<1%	41	$58.95
86695		<1%	78	$56.64
87070		<1%	152	$54.27
84702		<1%	33	$39.15
86038		<1%	44	$33.13
82465		<1%	68	$23.04
85652		<1%	92	$22.82
84479		<1%	60	$19.51
84144		<1%	16	$18.78
82248		<1%	67	$13.56
82977		<1%	16	$12.96
82540		<1%	20	$12.63
84466		<1%	14	$11.50
83721		<1%	43	$8.27
85610		<1%	17	$7.76
84478		<1%	43	$5.17
82040		<1%	22	$1.71
84450		0%	38	$0.00
86003		0%	70	$0.00
84100		0%	37	$0.00
84460		0%	50	$0.00
84550		0%	42	$0.00
85049		0%	21	$0.00
84480		0%	232	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHODGES, JEAN (CEO)